Danielle M. Lauzon

Danielle M. Lauzon

Danielle M. Lauzon

Danielle Lauzon is a partner in Goodwin’s Technology Companies & Life Sciences Group. From 2007 through 2012, Ms. Lauzon was recognized as Massachusetts Super Lawyer “Rising Star” for her work representing private and public companies on general corporate and securities law and mergers and acquisitions. Ms. Lauzon also represents issuers in connection with the public offering and private placement of equity securities, and has represented companies as well as venture capital and private equity firms in numerous venture capital financings and recapitalizations.

Ms. Lauzon currently serves on the hiring committee for Goodwin’s Boston office.

Professional Activities

Ms. Lauzon serves on the Board of Directors for Women Entrepreneurs in Science and Technologies (WEST). She is also a member of the Massachusetts and Boston Bar Associations.

Professional Experience

Prior to joining Goodwin, Ms. Lauzon was an associate in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston.


Ms. Lauzon has been recognized by The Legal 500 U.S. for her work in the life science industry, and from 2007 through 2012, she was recognized as a Massachusetts Super Lawyer "Rising Star" by Law & Politics and Boston magazine. In law school, Ms. Lauzon was a member of the Villanova Law Review.

Areas of Practice


Ms. Lauzon’s representation of start-up and later stage companies spans the entire corporate life cycle, including formation matters, general corporate representation and counseling, venture capital financings, public offerings and mergers and acquisitions. Her clients are in the life sciences, software and information technology services industries. Her recent representations include:

  • Onyx Pharmaceuticals in its $10.4 billion sale to Amgen, one of the largest biotech transactions ever
  • AMRI in its $174 million acquisition of Gadea Pharmaceutical Group
  • Alector LLC in its Series A, Series B and Series C financings
  • Promedior, Inc. in its strategic agreement with Bristol-Myers Squibb
  • Unum Therapeutics in its $65 million Series B financing
  • ProQR Therapeutics N.V. in its $97.5 million initial public offering
  • Blueprint Medicines in its $25 million Series B and $50 million Series C financings
  • AbilTo, Inc. in its Series A, Series B and Series C financings
  • Zalicus Inc. in its sale to Epirus Biopharmaceuticals
  • Moderna Therapeutics in the closing of a $110 million financing round
  • Hasbro, Inc., a global branded play company and owner of some of the world’s most popular brands, on its acquisition of a 70% interest in Backflip Studios, a developer and publisher of mobile games of IOS and Android devices
  • Picis Solutions in its sale to Ingenix, a subsidiary of UnitedHealth Group
  • Phase Forward in its sale to Oracle Corporation



J.D., 2000
Villanova University School of Law

(magna cum laude, Order of the Coif)

B.A., 1997
University of Michigan



Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers